Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H1 2018
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H1 2018
SUMMARY
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - 11beta-hydroxysteroid dehydrogenase type 1 is an NADPH-dependent enzyme highly expressed in key metabolic tissues including liver, adipose tissue, and the central nervous system.
In these tissues HSD11B1 reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. This enzyme plays an important role in obesity and insulin resistance.
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders, Ophthalmology, Central Nervous System, Cardiovascular, Immunology and Musculoskeletal Disorders which include indications Type 2 Diabetes, Obesity, Ocular Hypertension, Open-Angle Glaucoma, Alzheimer's Disease, Cardiomyopathy, Cushing's Syndrome, Dementia Associated With Alzheimer's Disease, Inflammation, Intracranial Hypertension, Metabolic Syndrome and Muscle Atrophy.
The latest report Corticosteroid 11 Beta Dehydrogenase Isozyme 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - 11beta-hydroxysteroid dehydrogenase type 1 is an NADPH-dependent enzyme highly expressed in key metabolic tissues including liver, adipose tissue, and the central nervous system.
In these tissues HSD11B1 reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. This enzyme plays an important role in obesity and insulin resistance.
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders, Ophthalmology, Central Nervous System, Cardiovascular, Immunology and Musculoskeletal Disorders which include indications Type 2 Diabetes, Obesity, Ocular Hypertension, Open-Angle Glaucoma, Alzheimer's Disease, Cardiomyopathy, Cushing's Syndrome, Dementia Associated With Alzheimer's Disease, Inflammation, Intracranial Hypertension, Metabolic Syndrome and Muscle Atrophy.
The latest report Corticosteroid 11 Beta Dehydrogenase Isozyme 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146)
- The report reviews Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics and enlists all their major and minor projects
- The report assesses Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Overview
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Companies Involved in Therapeutics Development
Actinogen Medical Ltd
AstraZeneca Plc
Boehringer Ingelheim GmbH
Connexios Life Sciences Pvt Ltd
F. Hoffmann-La Roche Ltd
Hyundai Pharmaceutical Co Ltd
Laboratorios SALVAT SA
Poxel SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
Toray Industries Inc
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Drug Profiles
AZD-4017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-135558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNX-1049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIS-388 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KR-66344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5093151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HSD11B1 for Muscle Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase 1 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SVT-63 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SVT-88 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-013A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UE-2343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Dormant Products
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Discontinued Products
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Product Development Milestones
Featured News & Press Releases
Mar 21, 2018: Mid-Way Point Reached in Landmark Alzheimer’s Trial - XanADu
Feb 12, 2018: Actinogen Medical: Strong Recruitment Progress in Alzheimer's Trial
Feb 06, 2018: Actinogen Medical: New data supports link between stress hormone cortisol and worsening cognition
Dec 01, 2017: Amgen Pioneer Dr George Morstyn Joins Actinogen Board
Nov 29, 2017: Early Efficacy and Safety Data Read-Out Planned for Alzheimer’s Trial
Nov 22, 2017: Leading Alzheimer's Researchers to Address Shareholders
Oct 30, 2017: Actinogen Medical: September Quarterly Update
Oct 16, 2017: Actinogen to be Showcased at Key Conferences
Oct 11, 2017: Actinogen Medical: Final major market patent granted for Xanamem
Sep 07, 2017: Actinogen Medical: First patient completes landmark Alzheimer's disease trial
Aug 16, 2017: First UK patient treated in ground-breaking Alzheimer’s clinical trial
Jul 26, 2017: Actinogen Medical Provides Update on Xanamem
Jul 19, 2017: Actinogen Medical presenting at Bioshares Biotech 2017 Summit
Jun 22, 2017: First US patients treated in landmark Alzheimers disease trial
Jun 01, 2017: First UK site goes live in global Alzheimer’s disease clinical trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Overview
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Companies Involved in Therapeutics Development
Actinogen Medical Ltd
AstraZeneca Plc
Boehringer Ingelheim GmbH
Connexios Life Sciences Pvt Ltd
F. Hoffmann-La Roche Ltd
Hyundai Pharmaceutical Co Ltd
Laboratorios SALVAT SA
Poxel SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
Toray Industries Inc
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Drug Profiles
AZD-4017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-135558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNX-1049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIS-388 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KR-66344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5093151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HSD11B1 for Muscle Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase 1 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SVT-63 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SVT-88 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-013A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UE-2343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Dormant Products
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Discontinued Products
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Product Development Milestones
Featured News & Press Releases
Mar 21, 2018: Mid-Way Point Reached in Landmark Alzheimer’s Trial - XanADu
Feb 12, 2018: Actinogen Medical: Strong Recruitment Progress in Alzheimer's Trial
Feb 06, 2018: Actinogen Medical: New data supports link between stress hormone cortisol and worsening cognition
Dec 01, 2017: Amgen Pioneer Dr George Morstyn Joins Actinogen Board
Nov 29, 2017: Early Efficacy and Safety Data Read-Out Planned for Alzheimer’s Trial
Nov 22, 2017: Leading Alzheimer's Researchers to Address Shareholders
Oct 30, 2017: Actinogen Medical: September Quarterly Update
Oct 16, 2017: Actinogen to be Showcased at Key Conferences
Oct 11, 2017: Actinogen Medical: Final major market patent granted for Xanamem
Sep 07, 2017: Actinogen Medical: First patient completes landmark Alzheimer's disease trial
Aug 16, 2017: First UK patient treated in ground-breaking Alzheimer’s clinical trial
Jul 26, 2017: Actinogen Medical Provides Update on Xanamem
Jul 19, 2017: Actinogen Medical presenting at Bioshares Biotech 2017 Summit
Jun 22, 2017: First US patients treated in landmark Alzheimers disease trial
Jun 01, 2017: First UK site goes live in global Alzheimer’s disease clinical trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Actinogen Medical Ltd, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Connexios Life Sciences Pvt Ltd, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2018
Pipeline by Laboratorios SALVAT SA, H1 2018
Pipeline by Poxel SA, H1 2018
Pipeline by Shionogi & Co Ltd, H1 2018
Pipeline by SK Chemicals Co Ltd, H1 2018
Pipeline by Toray Industries Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Actinogen Medical Ltd, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Connexios Life Sciences Pvt Ltd, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2018
Pipeline by Laboratorios SALVAT SA, H1 2018
Pipeline by Poxel SA, H1 2018
Pipeline by Shionogi & Co Ltd, H1 2018
Pipeline by SK Chemicals Co Ltd, H1 2018
Pipeline by Toray Industries Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
Actinogen Medical Ltd
AstraZeneca Plc
Boehringer Ingelheim GmbH
Connexios Life Sciences Pvt Ltd
F. Hoffmann-La Roche Ltd
Hyundai Pharmaceutical Co Ltd
Laboratorios SALVAT SA
Poxel SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
Toray Industries Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
Actinogen Medical Ltd
AstraZeneca Plc
Boehringer Ingelheim GmbH
Connexios Life Sciences Pvt Ltd
F. Hoffmann-La Roche Ltd
Hyundai Pharmaceutical Co Ltd
Laboratorios SALVAT SA
Poxel SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
Toray Industries Inc
